Repairing broken genes with CRISPR
Editas Medicine (editasmedicine.com) scores 82 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 80th percentile of 9950 Healthcare brands.
Editas Medicine is a discovery-phase pharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. It focuses on developing CRISPR gene editing technology to create genomic medicines for people living with serious diseases. The company aims to discover, develop, manufacture, and commercialize durable therapeutic treatments targeting unmet medical needs, positioning itself as a leader in the gene editing therapeutics space within the healthcare industry.
| Brand Name | Editas Medicine |
|---|---|
| Domain | editasmedicine.com |
| Industry | Healthcare |
| Founded | 2013 |
| Headquarters | Cambridge |
| Main Competitors | CRISPR Therapeutics (79/100), Intellia Therapeutics (84/100), Beam Therapeutics (76/100), Sangamo Therapeutics (84/100), Precision BioSciences |
Moz Domain Authority 57/100 vs category average 41 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #540,737 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Editas Medicine has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Editas Medicine is a leading gene editing company focused on developing CRISPR medicines for people with serious diseases." (Meta description: 18 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram, YouTube, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Editas Medicine?", Claude could identify the brand as of September 2026. Editas Medicine is a Cambridge, Massachusetts-based clinical-stage biotechnology company focused on developing gene editing therapies using CRISPR/Cas9 and CRISPR/Cas12a technology to treat genetic diseases. It was co-founded by pioneers in the CRISPR field and has worked on trea Best known for Being one of the first companies to bring CRISPR gene editing therapies into clinical trials.
When asked "Best brands similar to Editas Medicine?", Claude would recommend Editas Medicine as of September 2026. It's a well-known name in the gene editing space alongside companies like CRISPR Therapeutics and Intellia, so it would naturally come up in that context.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Editas Medicine's main competitors in Healthcare: CRISPR Therapeutics (79/100), Intellia Therapeutics (84/100), Beam Therapeutics (76/100), Sangamo Therapeutics (84/100).
Sources: Brand Analyzer scan
Editas Medicine is a discovery-phase pharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. It specializes in gene editing, using CRISPR technology to develop genomic medicines aimed at treating serious diseases.
Sources: Editas Medicine official site
Editas Medicine has moderate AI-search visibility, scoring 57/100 on Brand Analyzer's AI visibility composite (visibility 68, trust 37, recommendation 62). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Editas Medicine official site
Editas Medicine was founded in 2013. Editas Medicine operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Editas Medicine is headquartered in Cambridge. Editas Medicine operates in the Healthcare category.
Sources: Wikidata
Editas Medicine harnesses CRISPR gene editing technology to discover, develop, manufacture, and work toward commercializing genomic medicines. Its efforts are directed at creating a pipeline of treatments intended to address serious diseases with significant unmet medical needs.
Sources: Editas Medicine official site
Editas Medicine scores 62/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Editas Medicine official site
Editas Medicine can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Editas Medicine official site
Editas Medicine is known for being a leading company in the CRISPR gene editing field, focused specifically on developing genomic medicines for serious diseases. It is recognized within the biotechnology and healthcare sectors as a pioneer applying CRISPR technology to therapeutic development.
Sources: Editas Medicine official site
Editas Medicine's target audience includes people living with serious genetic diseases worldwide who may benefit from gene editing therapies, as well as the medical and scientific communities involved in researching and advancing gene editing treatments.
Sources: Editas Medicine official site
Editas Medicine scores 57/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Editas Medicine has a limited AI-visibility profile at 57/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (68/100) and its weakest is trust (37/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #540,737 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Editas Medicine from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Editas Medicine: Eczema UK (82/100), e-con Systems (82/100), ekincare (82/100), Elwyn (82/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.